Skip to main content
. 2014 Dec 19;5:5812. doi: 10.1038/ncomms6812

Figure 6. PR-lncRNA-1 and PR-lncRNA-10 modulate cell proliferation and apoptosis.

Figure 6

(a,b) HCT116 cells were transfected with two separate non-targeting ASOs (Ctrl-1 and Ctrl-2) or with two different ASOs (ASO-1 and ASO-2) targeting PR-lncRNA-1 or PR-lncRNA-10, separately or in combination (ASO pool), and treated with 150 nM DNA-damage Doxo for 12 h. Cell proliferation was measured by MTS assay up to 72 h (a,b). (c) Percentage of apoptotic cells measured by annexinV-7AAD (7-aminoactinomycin D) staining on cells transfected with the indicated ASOs and treated with the 350 μM DNA-damage drug 5-FU for 12 h. (d,e). Apoptosis was determined by quantification of caspase 3/7 levels in cells treated with 5-FU for 12 h and transfected with the indicated ASOs. (f–i) Cell cycle phase distribution analysed by propidium iodide staining of cells transfected with ASOs specific for PR-lncRNA-1 (f,g) or PR-lncRNA-10 (h,i) depletion and treated with the indicated drugs for 12 h. All graphs (a–i) represent the mean (±s.d.) of at least three independent experiments. Significance was determined by two-tailed unpaired t-test. *P<0.05 and **P<0.01.